Serie A1 (water polo)

Global Deep Venous Disease Treatment Devices Market is Expected to Reach $2.4 Billion by 2032: Rise in Diagnosis of Deep Venous Diseases in Hospitals Leading to Increased Use of Treatment Devices - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 19, 2023

The global deep venous disease treatment devices market is in the developed phase.

Key Points: 
  • The global deep venous disease treatment devices market is in the developed phase.
  • Among the sectors of the healthcare ecosystem that got less impacted by the pandemic are the deep venous disease treatment devices.
  • The global deep venous disease treatment devices market (by end user) is expected to be dominated by the hospitals and clinics segment.
  • The global deep venous disease treatment devices market (by region) is dominated by the North America segment.

Worlds Announces $21 Million Series A1 Funding Round to Scale Industrial Metaverse Platform

Retrieved on: 
Monday, January 9, 2023

Today, Worlds Enterprises, Inc., creators of a new 4D infrastructure for building the Industrial Metaverse, announces the successful completion of its $21.2 million Series A1 funding round.

Key Points: 
  • Today, Worlds Enterprises, Inc., creators of a new 4D infrastructure for building the Industrial Metaverse, announces the successful completion of its $21.2 million Series A1 funding round.
  • The funding will be used to continue investing in the Company’s AI platform, expand key go-to-market partnerships, and further expand the adoption of Worlds’ technology by industrial companies.
  • The Worlds Industrial Metaverse platform brings AI-based automation directly into the ground floor operations of large industrial companies.
  • This is why Align Capital is a proud partner and continues to invest in Worlds,” says Lisa Harris, Founder and Managing Partner, Align Capital.

Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines

Retrieved on: 
Wednesday, November 16, 2022

Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round.

Key Points: 
  • Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round.
  • We see significant commercial potential for a shingles vaccine that could match the clinical profile of Shingrix (currently annualizing at $3B in sales) without manufacturing capacity constraints.
  • As Curevo's oldest partner, we are proud to continue to support accessible vaccines to prevent shingles, stated EC Huh, PhD, GC Biopharmas President.
  • Its lead product is CRV-101, a sub-unit vaccine to prevent the reactivation of the varicella zoster virus (shingles) in older adults.

CMCT Declares Common and Preferred Stock Dividends

Retrieved on: 
Thursday, September 22, 2022

CMCT (NASDAQ: CMCT and TASE: CMCT-L) announced today that its Board of Directors has declared a quarterly cash dividend of $0.085 per share of common stock.

Key Points: 
  • CMCT (NASDAQ: CMCT and TASE: CMCT-L) announced today that its Board of Directors has declared a quarterly cash dividend of $0.085 per share of common stock.
  • In addition, the Board of Directors has declared a quarterly cash dividend of $0.34375 per share of CMCT's Series A Preferred Stock for the fourth quarter of 2022.
  • Further, the Board of Directors has declared a quarterly cash dividend of $0.375 per share of CMCT's Series A1 Preferred Stock for the fourth quarter of 2022.
  • The Board of Directors has also declared a quarterly cash dividend of $0.353125 per share of CMCTs Series D Preferred Stock for the fourth quarter of 2022.

European Quantum Computing Leader IQM Raises €128m Led by World Fund to Help Combat the Climate Crisis

Retrieved on: 
Friday, July 22, 2022

IQM Quantum Computers (IQM), the European leader in building superconducting quantum computers, is announcing today it has raised 128 million ($128m) in Series A2 funding led by World Fund to expand its international business and accelerate product development to tackle the worlds most pressing problems.

Key Points: 
  • IQM Quantum Computers (IQM), the European leader in building superconducting quantum computers, is announcing today it has raised 128 million ($128m) in Series A2 funding led by World Fund to expand its international business and accelerate product development to tackle the worlds most pressing problems.
  • IQM is also the only European company that is already delivering full-stack quantum systems.
  • Daria Saharova, Founding Partner at World Fund, said: Quantum computing holds the potential to drive the breakthroughs needed to help solve the climate crisis.
  • World Fund is the largest European-focused climate venture capital fund established by Daria Saharova, Danijel Vievi, Craig Douglas, and Tim Schumacher.

Micropep, Ag-biotech Innovator, Raises €8.75 Million From Global Syndicate to Bring Ground-breaking and Cost-effective Alternatives to Conventional Crop Protection Products to Market

Retrieved on: 
Tuesday, July 12, 2022

The new round of financing will fuel Micropeps expansion to the United States, making US-based venture fund, Fall Line Capital, a perfect partner.

Key Points: 
  • The new round of financing will fuel Micropeps expansion to the United States, making US-based venture fund, Fall Line Capital, a perfect partner.
  • Fall Line Capital is known for its commitment to sustainable agriculture through its strategic investments in both U.S. farmland and innovative AgTech companies.
  • "Micropep has developed a truly novel technology platform in ag-biotech that promises to bring farmers highly effective new and environmentally safe crop protection solutions.
  • Our unique approach could open new frontiers in crop protection the same way RNA technology did with vaccines."

CMCT Declares Common and Preferred Stock Dividends

Retrieved on: 
Friday, June 10, 2022

CMCT (NASDAQ: CMCT and TASE: CMCT-L) announced today that its Board of Directors has declared a quarterly cash dividend of $0.085 per share of common stock.

Key Points: 
  • CMCT (NASDAQ: CMCT and TASE: CMCT-L) announced today that its Board of Directors has declared a quarterly cash dividend of $0.085 per share of common stock.
  • Further, the Board of Directors has declared a quarterly cash dividend of $0.375 per share of CMCT's Series A1 Preferred Stock for the second and third quarter of 2022 (assuming there will be shares of Series A1 Preferred Stock issued in June).
  • The Board of Directors has also declared a quarterly cash dividend of $0.353125 per share of CMCTs Series D Preferred Stock for the third quarter of 2022.
  • For shares of Series A Preferred Stock, Series A1 Preferred Stock and Series D Preferred Stock issued during the third quarter of 2022, as the case may be, the dividend will be prorated from the date of issuance, and the monthly dividend payments will reflect such proration, as applicable.